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Decreased Levels of Serum Brain-Derived 
Neurotrophic Factor in Male Pediatric Patients 
with Depression 
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BACKGROUND: Brain-derived neurotrophic factor (BDNF) plays an important role 
in the pathophysiology of major depressive disorder (MDD). Several meta-analyses 
have shown decreased serum levels of BDNF in adult patients with MDD, but there has 
been no report on the serum levels of BDNF in pediatric patients with depression. In 
this study, we investigated whether serum levels of BDNF are altered in pediatric 
patients with depression. 
METHODS: We measured serum BDNF levels in the following four groups: male 
pediatric patients with depression (n = 13), female pediatric patients with depression (n 
= 17), and age-matched normal control subjects (n = 10 for Male, n=12 for Female). 
Patients were evaluated using the Children’s Depression Rating Scale Revised 
(CDRS-R). Serum levels of BDNF were measured with the sandwich ELISA method.  
RESULTS: Serum levels (6.97 ± 3.69 ng/mL [mean ± SD]) of BDNF in male pediatric 
patients with depression were significantly (p=0.019) lower than those (10.67 ± 3.11 
ng/mL) in the male control group. However, there was no difference between the female 
pediatric patients with depression (9.29 ± 4.61 ng/mL) and the female control group 
(10.21 ± 4.79 ng/mL). Furthermore, there was no correlation between serum levels of 
BDNF and CDRS-R scores in the pediatric patients with depression. Interestingly, there 
was a significant negative correlation (r = -0.683, p=0.010) between the serum BDNF 
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levels and the duration of illness in male, but not female, pediatric patients with 
depression.  
CONCLUSIONS: This study suggests that low BDNF levels may play a role in the 
pathophysiology of male pediatric patients with depression. 
Key Words: Biomarker, Brain-derived neurotrophic factor (BDNF), Pediatric 
depression, Serum 
Abbreviations: BDNF, Brain-derived neurotrophic factor; BPD, Bipolar disorders; 
MDD, Major depressive disorder; CDRS-R, Children’s Depression Rating Scale 
Revised. 
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Introduction 
Major depressive disorder (MDD) is a serious disorder that affects approximately 
17% of the population at some point in life, resulting in major social and economic 
consequences [1-3]. MDD in children and adolescents is characterized by one or more 
major depressive episodes, defined as at least 2 weeks of persistent change in mood 
manifested by either depressed or irritable mood or loss of interest or pleasure and at 
least four additional symptoms of depression [4]. Depression in children has been 
reported to be a common, recurrent and impairing condition associated with increased 
psychosocial and medical morbidity and mortality [5]. The prevalence of depression in 
children and in adolescences is 1-2% and 3-8%, respectively [6]. Depressive symptoms 
are also associated with significant functional impairments in school and work, frequent 
legal involvement [5-9], and increased risk for substance abuse and completed suicide 
[10-13]. However, the precise neurobiological mechanisms underlying the 
pathophysiology of pediatric depression are currently unknown. One way to combat this 
disorder would be to discover novel biomarkers for it. Identification of biomarkers 
would aid both in the diagnosis of this disorder, and in the development of effective 
psychiatric medications to treat it [14-18]. 
Multiple lines of evidence suggest that brain-derived neurotrophic factor (BDNF) 
plays an important role in the pathophysiology of MDD, as well as in the mechanisms 
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underlying the therapeutic actions of antidepressants [18-23]. Our group reported that 
serum BDNF levels were significantly lower in adult patients with MDD and eating 
disorders (anorexia nervosa and bulimia nervosa) than in healthy controls [24][25]. And 
that serum BDNF levels in adult patients with MDD were significantly increased after 
antidepressant treatment [24]. Four subsequent meta-analyses confirmed our findings 
[24,26-29]. Therefore, it is likely that the measurement of blood BDNF levels would be 
a potential biomarker for MDD [18]. However, there has been no report demonstrating 
the blood levels of BDNF in pediatric patients with depression. 
In this study, we examined whether serum levels of BDNF are altered in pediatric 
patients with depression. It has previously been reported that girls have twice the risk of 
developing depression after the onset of puberty compared to boys [30], and that a 
group of adolescent females scored lower on personal resilience and showed more 
depressive symptoms than adolescent males [31]. Therefore, to address this potential 
difference between sexes, we performed our analysis separately in male and female 
pediatric patients. 
2. Methods and Materials 
2.1. Patients 
Thirteen male patients with pediatric depression (age: 13.0 years [SD 1.00]; 
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range: 11–14 years) and 17 female patients with pediatric depression (age: 12.94 years 
[SD 1.85]; range: 8–15 years) were recruited from Chiba University Hospital (Table 1). 
Age and ethnicity-matched healthy male pediatric subjects (age: 14.30 years [SD 2.80]; 
range: 9–17 years) and female pediatric subjects (age: 11.50 years [SD 3.71]; range: 
7–17 years) also participated in this study as normal control subjects (Table 1). The 
ethics committee of Chiba University Graduate School of Medicine approved the study 
protocol, and all of the subjects provided written informed consent for participation in 
the study. All pediatric patients with depression (F32) were diagnosed according to the 
ICD-10 criteria [32], and were classified as having one of three subtypes (Mild 
Depressive Episode type [n =5], Moderate Depressive Episode type [n = 21] or Severe 
Depressive Episode type [n = 4]). All subjects completed the Children’s Depression 
Rating Scale-Revised (CDRS-R). The CDRS-R was used to measure children’s 
depressive symptomatology [33]. The durations of illness in the male patients with 
pediatric depression and female patients with pediatric depression were 12.08 ± 10.95 
months and 10.06 ± 10.6 months, respectively (Table 1). The antidepressants 
administered for treatment were milnaciplan (25-125 mg/day; n = 4), fluvoxamine 
(50–100 mg/day; n = 3), sulpiride (50-100 mg/day; n = 3), and perospirone (4 mg/day; 
n = 1). Nineteen of the patients were drug-naive. Healthy controls were recruited from 
7 
 
Chiba-City by advertisement. All control group participants underwent a comprehensive 
assessment of medical history to eliminate individuals with any neurological or other 
medical disorders. The Structured Clinical Interview MINI-KID [34] was also 
conducted in order to determine the existence of any personal or familial history of past 
or present mental illness. None of the control subjects initially recruited was found to 
fulfill these exclusion criteria. 
2.2. Procedures 
Serum samples from the patients and normal control subjects were collected 
between 10:00 to15:00, and were stored at -80°C until they were used for the assay. 
Serum levels of BDNF were measured by using the BDNF Emax Immunoassay System 
kit (Promega, Madison, WI) according to the manufacturer’s instructions. To minimize 
the assay variance, serum BDNF levels were measured in all subjects on the same day. 
Briefly, 96-well plates were coated with anti-BDNF monoclonal antibody and incubated 
at 4°C for 18 hours. The plates were then incubated in a blocking buffer for 1 hour at 
room temperature. Next, the samples and the BDNF standards were maintained at room 
temperature and shaken for 2 hours, followed by washing with the washing buffers. The 
plates were incubated with antihuman BDNF polyclonal antibody at room temperature 
for 2 hours, washed, and incubated with anti-immunoglobulin Y antibody conjugated to 
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horseradish peroxidase for 1 hour at room temperature. Finally, an incubation in 
peroxidase substrate and tetramethylbenzidine solution was conducted to produce a 
color reaction. The reaction was stopped with 1 mol/L hydrochloric acid and absorbance 
at 450 nm was measured with an automated microplate reader (Emax; Molecular 
Devices, Sunnyvale, CA). 
2.3. Statistical Analysis 
The data were presented as the mean ± standard deviation (S.D.). The statistical 
analysis of the two groups was performed using Student’s t-test. The relationship 
between two variables was ascertained using Pearson’s correlation coefficients. Values 
of p<0 .05 were considered statistically significant. 
3. Results 
Serum levels of BDNF in male pediatric patients with depression (6.97 ± 3.69 
ng/ml) were significantly (t=2.548, p=0.019) lower than those of healthy male controls 
(10.67 ± 3.11 ng/ml). However, there was no difference among the drug-naive group 
(n=6), medicated group (n=7), and control group (n=10). There was also no correlation 
between serum levels of BDNF and CDRS-R scores in male patients. Interestingly, 
there was a significant negative correlation (r = -0.683, p=0.010) between the serum 
BDNF levels and the duration of illness in male pediatric patients with depression 
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(Figure 2). 
Serum levels of BDNF in female pediatric patients with depression (9.29 ± 4.61 
ng/ml) were not different (t=1.544, p=0.609) from those of healthy female controls 
(10.21± 4.79 ng/ml) (Table 1 and Figure 1). There was no difference among the 
drug-naive group (n=12), medicated group (n=5), and control group (n=12). There was 
no correlation between serum levels of BDNF and CDRS-R scores in female patients.  
4. Discussion 
In this study, we found that serum BDNF levels in male pediatric patients with 
depression were significantly lower than those of age-matched normal male controls. To 
the best of our knowledge, this is the first report demonstrating decreased serum levels 
of BDNF in male, but not female, pediatric patients with depression. Very recently, 
Pandey et al. [35] reported that the levels of BDNF mRNA in the lymphocytes were 
significantly decreased in a group of pediatric depressed patients compared with 
age-matched normal controls, and that the levels of BDNF protein in the cytosol 
fraction of platelets were significantly decreased in the pediatric depressed patients 
compared with normal controls. Furthermore, the levels of BDNF in the cytosol fraction 
of platelets from drug-free, male pediatric patients with depression were significantly 
lower than those of age-matched normal controls [35], consistent with our data on male 
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pediatric patients with depression. However, the BDNF protein levels in the cytosol 
fraction of platelets obtained from female pediatric patients with depression were also 
significantly decreased compared with normal controls in this previous study [35], 
which was not consistent with our study. The reasons for this discrepancy are currently 
unknown. One possibility may be that the disparate results were attributable to the 
difference in the race of the subjects enrolled. That is, in the study by Pandey et al. [35] 
there were Asian, black, Hispanic, and white control and depressed patients, whereas in 
our study all the subjects were Japanese. Another possible cause was the difference in 
the source of blood sample (serum vs. platelets). Clearly, a further study using a large 
sample size will be needed to resolve the discrepancy. 
In this study, unlike in male subjects, we did not find any difference of serum 
BDNF levels between female pediatric patients with depression and female control 
subjects. The reasons underlying this gender difference are unknown. It is well known 
that prior to puberty the prevalence of depression is roughly equal in both sexes, but 
from puberty onwards, depression is more common in females [36], indicating a gender 
difference in pediatric depression. Therefore, it is likely that biological, hormonal, and 
psychosocial changes in female subjects contribute to the gender difference, although a 
further detailed study will be needed to confirm this idea. 
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It has also been reported that blood levels of BDNF are decreased in adult 
patients with bipolar disorders (BPD) during manic, depressed and even euthymic states, 
although these findings were not replicated in other reports [18]. A recent meta-analysis 
study demonstrated that patients with BPD had lower levels of BDNF than healthy 
controls [37]. In addition, BDNF levels were significantly increased after the 
pharmacological treatment of the manic state. These findings indicate that BDNF levels 
are abnormally reduced in manic and depressed states of BPD, and that the reduced 
level in the manic state increases after pharmacological treatment. There is a possibility 
that onset of BPD or schizophrenia will occur in some children with depression. It may 
therefore be of interest to measure serum BDNF levels in children with and without 
depression in order to determine the role of BDNF as a serological marker in children 
who later develop BPD or schizophrenia. 
In this study, we found a significant negative correlation (r = -0.683, p=0.010) 
between the serum levels of BDNF and the duration of illness in male pediatric patients 
with depression. It should be noted that serum BDNF levels are negatively related with 
the duration of illness, since longstanding depression in adolescence is a powerful 
predictor of continued mental health problems in adulthood [38].  
The main limitation of this study is the small sample size (male patient n=13, 
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female patient n=17). Therefore, a further study using a large sample size will be 
necessary. Another limitation of this study may be the effects of medication since 
antidepressants could affect serum BDNF levels. Therefore, a further study using 
antidepressant-untreated patients will be also needed. 
5. Conclusion 
In conclusion, this study suggests that decreased levels of BDNF may play a role 
in the pathophysiology of male patients with pediatric depression, although a further 
study using a large sample size will be needed.  
13 
 
Figure legends 
 
Figure1. Serum levels of BDNF in pediatric patients with depression (PD) and normal 
controls (NC). The blue diamonds represent drug naïve patients, and the red squares 
represent medicated patients. Serum levels of BDNF in male (M) pediatric patients with 
depression (6.97 ± 3.69 ng/ml) were significantly (t=2.548, p=0.019) lower than those 
of normal male controls (10.67 ± 3.11 ng/ml). In contrast, serum levels of BDNF in 
female (F) pediatric patients with depression (9.29 ± 4.61 ng/ml) were not different 
(t=1.544, p=0.609) from those of normal female controls (10.21± 4.79 ng/ml). 
 
Figure 2. Relationship between the serum levels of BDNF and the duration of illness in 
male pediatric subjects with depression. There was a significant negative correlation (r 
= -0.683, p=0.010) between the serum levels of BDNF and the duration of illness in 
male pediatric patients (n=13) with depression. 
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Table 1. Demographic characterization of patients with pediatric depression and normal controls 
        
  Male Male     Female Female   
  Control (n=10) Depression (n=13) p-Values 
 
Control (n=12) Depression (n=17) p-Values 
  
      
  
Age (years) 
14.30 ± 2.80  
(9-17) 
13.0 ± 1.00  
(11-14) 
0.1374 
 
11.50 ± 3.71  
(7-17) 
12.94 ± 1.85  
(8-15) 
0.1777 
Duration of illness 
(months) 
- 
12.08 ± 10.95  
(1-36) 
- 
 
- 
10.06 ± 10.60  
(1-39) 
- 
CDRS-R Score - 
56.08 ± 20.46  
(27-97) 
- 
 
- 
55.29 ± 13.50 
(35-84) 
- 
BDNF (ng/mlL) 10.67 ± 3.11 6.97 ± 3.69 0.0187*   10.21 ± 4.79 9.29 ± 4.61 0.6089 
Values are the mean ±SD. Values in parenthesis are the range.  
BDNF: brain-derived neurotrophic factor. CDRS-R: Children's Depression Rating Scale-Revised.  
Statistical analysis was performed by Student’s t-test. *Statistically significant at p<0.05. 
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